Figure 4.

sFVA‐mediated bone marrow leukemia cell targeting and biodistribution of hybrid nanoparticle in U937‐bearing orthotopic AML model. a) Experimental procedures and FACS gating strategy for bone marrow cells. NSG mice 4–6 week old were infused with U937 cells and intravenously injected with hybrid nanoparticle at day 6 post cell infusion. At 2 h after nanoparticle injection, bone marrow cells were harvested from the femur and tibia and analyzed by flow cytometry. b) Representative dot plot of nanoparticle uptake for human CD33+ bone marrow U937 cells. c) Representative dot plot of nanoparticle uptake for mouse CD45+ CD11b+ bone marrow immune cells. d) Bar graph for the percentage of nanoparticle uptake for U937 and mouse immune cells. Data are presented as mean ± SD (n = 3–4 per group). e) Representative organ image for biodistribution of hNP and T‐hNP. f) Total radiant efficiency for organ distribution of nanoparticles at 24 h post injection. Total radiant efficiency for femur and tibia indicates sum of left and right femur and tibia and compared to other organs. g) Average radiant efficiency for nanoparticles in femur and tibia. Each dot indicates fluorescence intensity for left or right femur and tibia. Data are presented as mean ± SD (n = 3 per group). All statistical analyses were performed by one‐way ANOVA with Bonferroni's test, *p < 0.05, ***p < 0.001, n.s = not significant.